Futurescaping of Oncology A Technology Sampler of Potential Paradigm Changing Approaches to Treating Cancer

Demy-Colton: Virtual Salon Series

September 9, 2020

[ Click here to view recording ]


  • Sara Demy, CEO, Demy-Colton


  • Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting, Previously Defined Health


  • Jacob Becraft, PhD, Co-founder, CEO, Strand Therapeutics
  • Jennifer C. Petter, PhD Founder, CSO, Arrakis Therapeutics
  • Arthur T. Sands, MD, PhD, CEO, Board of Director, Nurix Therapeutics

Futurescaping of Oncology will look at forward-looking, key, therapeutically relevant technology advances that could change the way we treat cancer. Three novel platforms will be discussed including endogenous reprogramming, targeting RNA, and targeting undruggable protein targets. These platforms were chosen to reflect a range of approaches, risks, degrees of validation, and complexity of engineering. These platforms are great examples of higher-level technologies that will take cancer therapies to the next level.